SPAIN: Advanced medical research conducted at Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) as a collaborative effort between Phytoplant Research SL, VivaCell Biotechnology España SL, and Emerald Health Pharmaceuticals has unveiled the potent neuroprotective ability of Δ9-THCA, a phytocannabinoid produced in Cannabis sativa L. The research paper was accepted and published in the British Journal of Pharmacology.
The findings suggest that Δ9-THCA can potentially protect brain cells from degenerative diseases, such as Huntington’s disease, and could be a viable treatment option for patients suffering from debilitating neurodegenerative diseases such as multiple sclerosis (MS), Alzheimer’s and Parkinson’s disease.
“We demonstrated that Δ9-THCA, the main non psychoactive phytocannabinoid biosynthesized by the Cannabis sativa L. plant, exerts neuroprotective action in its raw form without acting on the endocannabinoid system, but by activating the PPARγ receptors, thereby avoiding the undesired psychotropic effects. This finding will open a new range of cannabinoid neuroprotective applications,” said Dr. Xavier Nadal, Manager, Extraction R&D Department, Phytoplant Research SL.
Δ9-THCA is not only the most abundant non-psychoactive cannabinoid found in marijuana but also an acidic phytocannabinoid. PPARγ is the nuclear receptor for some cannabinoids and PPARγ signalling has a role in neuroinflammation and epilepsy. As a potent PPARγ agonist, this effectual neuroprotectant exhibited neuroprotective and neuroinflammatory activity in an animal model of Huntington’s disease (HD).